FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215442024> ?p ?o ?g. }

• W3215442024 endingPage "120" @default.
• W3215442024 startingPage "117" @default.
• W3215442024 abstract "EpigenomicsVol. 14, No. 3 EditorialCombination therapy and noncoding RNAs: a new era of cancer personalized medicinePerla PucciPerla Pucci *Author for correspondence: E-mail Address: pp504@cam.ac.ukhttps://orcid.org/0000-0003-1264-3487Department of Pathology, Division of Cellular & Molecular Pathology, University of Cambridge, Cambridge, CB2 0QQ, UKSearch for more papers by this authorPublished Online:2 Dec 2021https://doi.org/10.2217/epi-2021-0405AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancercombination therapylong noncoding RNAsmiRNAstargeted therapyPapers of special note have been highlighted as: • of interestReferences1. Leucci E, Vendramin R, Spinazzi M et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature 531(7595), 518–522 (2016).Crossref, Medline, CAS, Google Scholar2. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics – challenges and potential solutions. Nat. Rev. Drug Discov. 20(8), 629–651 (2021).Crossref, Medline, CAS, Google Scholar3. Pucci P, Rescigno P, Sumanasuriya S, de Bono J, Crea F. Hypoxia and noncoding RNAs in taxane resistance. Trends Pharmacol. Sci. 39(8), 695–709 (2018).Crossref, Medline, CAS, Google Scholar4. Pencheva N, Tran H, Buss C et al. Convergent multi-miRNA targeting of ApoE grives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell 151(5), 1068–1082 (2012).Crossref, Medline, CAS, Google Scholar5. Tasaki Y, Suzuki M, Katsushima K et al. Cancer-specific targeting of taurine-upregulated gene 1 enhances the effects of chemotherapy in pancreatic cancer. Cancer Res. 81(7), 1654–1666 (2021). • Use of long noncoding RNA (lncRNA)-targeting antisense oligonucleotides (ASOs) to inhibit cancer growth.Crossref, Medline, CAS, Google Scholar6. Pucci P, Venalainen E, Alborelli I et al. LncRNA HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. Epigenomics 12(13), 1123–1138 (2020). • Use of lncRNA-targeting ASOs to inhibit cancer growth.Link, CAS, Google Scholar7. Zhen S, Lu J, Chen W, Zhao L, Li X. Synergistic antitumor effect on bladder cancer by rational combination of programmed cell death 1 blockade and CRISPR-Cas9-mediated long non-coding RNA urothelial carcinoma associated 1 knockout. Hum. Gene Ther. 29(12), 1352–1363 (2018).Crossref, Medline, CAS, Google Scholar8. Xue W, Dahlman JE, Tammela T et al. Small RNA combination therapy for lung cancer. PNAS USA 111(34), E3553–E3561 (2014).Crossref, Medline, CAS, Google Scholar9. Li Y, Jia F, Deng X et al. Combinatorial miRNA-34a replenishment and irinotecan delivery: via auto-fluorescent polymeric hybrid micelles for synchronous colorectal cancer theranostics. Biomater. Sci. 8(24), 7132–7144 (2020).Crossref, Medline, CAS, Google Scholar10. Lo YL, Wang CS, Chen YC et al. Mitochondrion-directed nanoparticles loaded with a natural compound and a microrna for promoting cancer cell death via the modulation of tumor metabolism and mitochondrial dynamics. Pharmaceutics 12(8), 1–23 (2020).Crossref, Google Scholar11. Jia F, Li Y, Deng X et al. Self-assembled fluorescent hybrid nanoparticles-mediated collaborative lncRNA CCAT1 silencing and curcumin delivery for synchronous colorectal cancer theranostics. J. Nanobiotechnol. 19(1), 1–15 ( 2021).Crossref, Medline, Google Scholar12. Yue R, Chen M, Ma N. Dual microRNA-triggered drug release system for combined chemotherapy and gene therapy with logic operation. ACS Appl. Mater. Interfaces 12(29), 32493–32502 (2020).Crossref, Medline, CAS, Google Scholar13. Hong DS, Kang YK, Borad M et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumors. Br. J. Cancer 122(11), 1630–1637 (2020). • Clinical trials or approval of non coding RNAs (ncRNAs) clinical use.Crossref, Medline, CAS, Google Scholar14. Leyten GHJM, Hessels D, Jannink SA et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 65(3), 534–542 (2014). • Clinical trials or approval of ncRNAs clinical use.Crossref, Medline, CAS, Google Scholar15. US National Library of Medicine. Clinical Trials.gov – clinical evaluation of the PROGENSA (registered trademark) prostate cancer gene 3 (PCA3) assay in men with a previous negative biopsy result (PCA3) (2019) https://clinicaltrials.gov/ct2/show/NCT01024959 • Clinical trials or approval of ncRNAs clinical use.Google Scholar16. Vernon M, Lambert B, Meryet-Figuière M et al. Functional miRNA screening identifies wide-ranging antitumor properties of miR-3622b-5p and reveals a new therapeutic combination strategy in ovarian tumor organoids. Mol. Cancer Ther. 19(7), 1506–1519 (2020). • Example of the multifaceted novel uses that ncRNAs can have in cancer research.Crossref, Medline, CAS, Google Scholar17. Tseng YY, Moriarity BS, Gong W et al. PVT1 dependence in cancer with MYC copy-number increase. Nature 512(1), 82–86 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByIntraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized deliveryManisha Pandey, Pung Xiau Wen, Giam Mun Ning, Gan Jia Xing, Liu Man Wei, Dinesh Kumar, Jayashree Mayuren, Mayuren Candasamy, Bapi Gorain, Neha Jain, Gaurav Gupta & Kamal Dua25 January 2023 | Nanomedicine, Vol. 17, No. 24 Vol. 14, No. 3 Follow us on social media for the latest updates Metrics Downloaded 47 times History Received 19 October 2021 Accepted 8 November 2021 Published online 2 December 2021 Published in print February 2022 Information© 2021 Future Medicine LtdKeywordscancercombination therapylong noncoding RNAsmiRNAstargeted therapyFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W3215442024 created "2021-12-06" @default.
• W3215442024 creator A5091745148 @default.
• W3215442024 date "2022-02-01" @default.
• W3215442024 modified "2023-09-23" @default.
• W3215442024 title "Combination therapy and noncoding RNAs: a new era of cancer personalized medicine" @default.
• W3215442024 cites W1977572305 @default.
• W3215442024 cites W2060088882 @default.
• W3215442024 cites W2106641840 @default.
• W3215442024 cites W2171001108 @default.
• W3215442024 cites W2311921258 @default.
• W3215442024 cites W2805241737 @default.
• W3215442024 cites W2901756871 @default.
• W3215442024 cites W3015098352 @default.
• W3215442024 cites W3021203926 @default.
• W3215442024 cites W3037705037 @default.
• W3215442024 cites W3038909192 @default.
• W3215442024 cites W3048643352 @default.
• W3215442024 cites W3093561780 @default.
• W3215442024 cites W3134119394 @default.
• W3215442024 cites W3159464455 @default.
• W3215442024 cites W3171835979 @default.
• W3215442024 doi "https://doi.org/10.2217/epi-2021-0405" @default.
• W3215442024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34852634" @default.
• W3215442024 hasPublicationYear "2022" @default.
• W3215442024 type Work @default.
• W3215442024 sameAs 3215442024 @default.
• W3215442024 citedByCount "3" @default.
• W3215442024 countsByYear W32154420242022 @default.
• W3215442024 crossrefType "journal-article" @default.
• W3215442024 hasAuthorship W3215442024A5091745148 @default.
• W3215442024 hasConcept C104317684 @default.
• W3215442024 hasConcept C145059251 @default.
• W3215442024 hasConcept C502942594 @default.
• W3215442024 hasConcept C54355233 @default.
• W3215442024 hasConcept C60644358 @default.
• W3215442024 hasConcept C62203573 @default.
• W3215442024 hasConcept C67705224 @default.
• W3215442024 hasConcept C71924100 @default.
• W3215442024 hasConcept C86803240 @default.
• W3215442024 hasConceptScore W3215442024C104317684 @default.
• W3215442024 hasConceptScore W3215442024C145059251 @default.
• W3215442024 hasConceptScore W3215442024C502942594 @default.
• W3215442024 hasConceptScore W3215442024C54355233 @default.
• W3215442024 hasConceptScore W3215442024C60644358 @default.
• W3215442024 hasConceptScore W3215442024C62203573 @default.
• W3215442024 hasConceptScore W3215442024C67705224 @default.
• W3215442024 hasConceptScore W3215442024C71924100 @default.
• W3215442024 hasConceptScore W3215442024C86803240 @default.
• W3215442024 hasIssue "3" @default.
• W3215442024 hasLocation W32154420241 @default.
• W3215442024 hasLocation W32154420242 @default.
• W3215442024 hasOpenAccess W3215442024 @default.
• W3215442024 hasPrimaryLocation W32154420241 @default.
• W3215442024 hasRelatedWork W2520085705 @default.
• W3215442024 hasRelatedWork W2529033627 @default.
• W3215442024 hasRelatedWork W2562438098 @default.
• W3215442024 hasRelatedWork W2801439262 @default.
• W3215442024 hasRelatedWork W2942701448 @default.
• W3215442024 hasRelatedWork W2981291069 @default.
• W3215442024 hasRelatedWork W3104684592 @default.
• W3215442024 hasRelatedWork W3109207856 @default.
• W3215442024 hasRelatedWork W4281692159 @default.
• W3215442024 hasRelatedWork W906615614 @default.
• W3215442024 hasVolume "14" @default.
• W3215442024 isParatext "false" @default.
• W3215442024 isRetracted "false" @default.
• W3215442024 magId "3215442024" @default.
• W3215442024 workType "article" @default.